

Infection

12 (1984), No 4 (July/August)

Untersuchung zur Pathogenese der Staphylokokkeninfektion von Kunststoffimplantaten und intravasalen Kathetern. (Peters, G.: Hygiene-Inst. der Univ., Goldenfeldstr. 19-21, 5000 Köln 41) S. 235.

Interferon Production in Male Homosexuals with the Acquired Immune Deficiency Syndrome (AIDS) or Generalized Lymphadenopathy. (Abb, J. et al.; Max von Pettenkofer-Inst., Pettenkoferstr. 9a, 8000 München 2) S. 240.

Bacteremia in a Swedish University Hospital: A One-year Prospective Study in 1981 and a Comparison with 1975-76. (Ljungman, P. et al.; Department of Internal Medicine, Huddinge Univ. Hospital, S-141 86 Huddinge) S. 243.

Clinicopathological Response of HBsAg-Positive Chronic Active Hepatitis to Adenine Arabinoside: Lack of Correlation with DNA Polymerase Response. (Liaw, Y. F. et al.; Liver Unit, Chang-Gung Memorial Hospital, Lin-Kou Medical Center, Taipei, Taiwan) S. 248.

The Three-year Incidence of Non-B Viral Hepatitis Morbidity in a Controlled Trial of Pre-exposure Immune Serum Globulin Prophylaxis. (Kark, J. D. et al.; Dept. of Social Medicine, Hadassah Medical Organization and the Hebrew Univ.-Hadassah School of Public Health and Community Medicine, Faculty of Medicine, Ein Kerem, Jerusalem, Israel) S. 251.

Bacterial-mycotic Liver Abscess in a Non-immunocompromised Host. (Niebel, J. et al.; Med. Klinik Innenstadt der Univ., Ziemssenstr. 1, 8000 München 2) S. 256.

Spinal Epidural Abscess: An Unusual Complication of Bacterial Endocarditis. (Elian, D. et al.; Dept. of Medicine A, The Chaim Sheba Med. Center and Tel-Aviv Univ. Sackler School of Med., Tel-Hashomer 52621, Israel) S. 258.

Actinobacillus actinomycetem-comitans Endocarditis in a Child with a Prosthetic Heart Valve. (Fellius, A. et al.; Univ. Children's Hospital "Het Wilhelmina Kinderziekenhuis", Nieuwegracht 137, NL-3513 LK Utrecht) S. 260.

Brain Abscess due to Streptococcus moniliformis and Actinobacterium mayeri. (Dijkmans, B. A. C. et al.; Dept. of Infectious Diseases, Univ. Hospital, NL-Leiden) S. 262.

Cytomegalovirus Infection with Perfusion Defects on the Lung Scan. (Boers, M., Haak, A.; Dept. of Internal Medicine, Bronovo Hospital, Bronovoelaan 5, NL-2597 AX The Hague) S. 265.

Serratia rubidaea Isolated from a Silastic Foam Dressing. (Parment, P. A. et al.; Dept. of Infectious Diseases, Univ. of Lund, Malmö General Hospital, S-214 01 Malmö) S. 268.

A Randomized Double-blind Investigation of Cefroxadine (CGP 9000) versus Cephalexin in Urinary Tract Infection. (Hess, J. et al.; Dept. of Urology, Herlev Hospital, Univ. of Copenhagen, Herlev Ringvej, DK-2730 Herlev) S. 270.

A Comparison of Oxytetracycline and Trimethoprim in the Treatment of Chlamydia trachomatis Urethritis. (Bo Nielsen, P. et al.; Statens Seruminst., Dept. of Clinical Microbiology, Hvidovre Hospital, Univ. of Copenhagen, Kettegærd Alle 30, DK-2650 Hvidovre) S. 274.

Fusidic Acid for the Treatment of Antibiotic-associated Colitis Induced by Clostridium difficile. (Cronberg, S. et al.; Dept. of Infectious Diseases, General Hospital, S-214 01 Malmö) S. 276.

Antibakterielle Aktivität von Clindamycin und Linkomycin in Bouillon, Serum und in Kombination mit Polymorphkernen Granulozyten gegen Staphylococcus aureus und Staphylococcus epidermidis. (Bassler, M. et al.; Klinikhygiene der Univ. Kliniken Freiburg, Hugstetterstr. 55, 7800 Freiburg) S. 280.

Chemotherapeutic Properties of the New Cephalosporin Antibiotic HR810 in Laboratory Animals. (Kiesel, N. et al.; Hoechst Aktiengesellschaft, Dept. for Chemotherapy, Postfach 800320, 6230 Frankfurt/Main 80) S. 286.

In vitro Activity of Fosfomycin Against Methicillin-susceptible and Methicillin-resistant Staphylococcus aureus. (Graniinger, W. et al.; Dept. of Chemotherapy, Univ. Lazaretg. 14, A-1090 Wien) S. 293.

Rotavirus Infection and Otitis Media. (Hadziselimovic, F. et al.; Univ. Children's Hospital, Römergasse 8, CH-4056 Basel) S. 296

Interleukin 2 Therapy in Infectious Diseases: Rationale and Prospects. (Siegel, J. P. et al.; Division of Virology, Office of Biologics Research and Review, FDA, 8800 Rockville Pike, Bethesda, MD 20205, USA) S. 298.

Monoclonal Antibodies: Technology and Application to Gram-negative Infections. (Young, L. S.; Division of Infectious Diseases, Univ. Los Angeles, California 90024, USA) S. 303.

Studies on Immunity Against Escherichia coli K13 with Monoclonal Anti-K13 and Anti-anti-K13. (Söderström, T. et al.; Dept. of Clinical Immunology, Univ. S-Göteborg) S. 309.

12 (1984), Nr. 5 (September/October)

Toxoplasmosis in Immunosuppression and AIDS. (Velimirovic, B.; Coordinator for AIDS, WHO European Regional Office, Weilburgstr. 20/2/15, A-2500 Baden bei Wien) S. 315.

Nutrient Chemotactic Agents and the In vitro Selective Control of Bacterial Colonization. (Sugarman, B., Epps, L. R.; Bldg. 1A, Room 620, VA Medical Center, 2002 Holcombe Blvd., Houston, Texas 77211, USA) S. 318.

Effect of Lipopolysaccharides, Lipid A and Interferon on the Cell-mediated Cytotoxicity of Human Leukocytes Against K-562 Tumor Cells. (Fink, P. C. et al.; Inst. für Laboratoriumsmedizin - Zentrallabor, Zentralkrankenhaus, St.-Jürgen-Str., 2800 Bremen 1) S. 322.

White Blood Cell Count, Erythrocyte Sedimentation Rate and Serum C-reactive Protein in Meningitis: Magnitude of the Response Related to Bacterial Species. (Velimirovic, P.; Dept. of Pediatrics, Univ. Central Hospital, SF-90220 Oulu 22) S. 328.

Serological Diagnosis of Erythema migrans Disease and related Disorders. (Wilske, B. et al.; Max von Pettenkofer-Inst. für Hygiene und Med. Mikrobiologie, Pettenkoferstr. 9a, 8000 München 2) S. 331.

Limited Value of Acyclovir in the Treatment of Uncomplicated Herpes Zoster: A Placebo-controlled Study. (van Broek, P. J. et al.; Univ. Hospital, Dept. of Infectious Diseases, Rijnsburgerweg 10, NL-2333 AA Leiden) S. 338.

Staphylococcus epidermidis als Infektionserreger in der Unfallchirurgie. (Hansis, M., Weller, S.; Berufsgenossenschaftliche Unfallklinik, Rosenauer Weg 95, 7400 Tübingen) S. 342.

Absorption of Erythromycin Stearate and Enteric-coated Erythromycin Base After a Single Oral Dose Immediately Before Breakfast. (Schreiner, A., Digranes, A.; Medical Dept. B, Univ. of Bergen, N-5016 Haukeland sykehus) S. 345.

Comparison Between Two Non-absorbable Antibiotic Regimes for Decontamination of the Oropharynx. (Borthen, L. et al.; Dept. of Oral Microbiology, Karolinska Inst., Univ.-Hospital, S-14186 Stockholm) S. 349.

Ciprofloxacin Concentrations in Tonsils Following a Single Intravenous Infusion. (Faless, N. et al.; ENT Clinic of the Univ., Anichstr. 35, A-6020 Innsbruck) S. 355.

A Case of Lyme Disease With Cardiac Involvement in the Netherlands. (Houwzerij, J. et al.; Dept. of Internal Medicine and Cardiology, Bonifatius Hospital, Medical Centre, NL-8917 CR Leeuwarden) S. 358.

Chloramphenicol-resistant *Salmonella* tennessee Osteomyelitis. (Kies, W. et al.; Children's Hospital, Univ. Lindwurmstr. 4, 8000 München 2) S. 359.

TumorDiagnostik & Therapie

5 (1984), Nr. 4 (August)

Vorkommen und Bedeutung von Thyreoglobulin, Tissue Polypeptide Antigen, carcinoembryonalem Antigen und Calcitonin in Gewebe und im Plasma von Schilddrüsenkarzinom-Patienten. (Oehr, P. et al.; Inst. für Nuklearmedizin der Univ., Sigmund-Freud-Str. 25, 5300 Bonn-Venusberg) S. 129.

The Efficiency of hTG-Ria as a Tool for Detecting Metastases and Local Recurrence of Thyroid Carcinoma. (Falk, U. et al.; SD: Abel, U.; Deutsches Krebsforschungszentrum, Inst. 09 Im Neuenheimer Feld 280, 6900 Heidelberg) S. 139.

Bone-Marrow Transplantation for Acute Leukaemia in First Remission. (Mahmoud, H. K. et al.; Innere Klinik und Poliklinik [Tumorforschung], Westdeutsches Tumorzentrum, Univ. Klinikum, Hufelandstr. 55, 4300 Essen) S. 144.

Die Pharmakokinetik von cis-Diaminodichloroplatin. (Ehninger, G. et al.; Med. Univ. Klinik, Otfried-Müller-Str., 7400 Tübingen) S. 147.

Krankheitsorientierte Phase-II-Studie mit Etoposid (NSC 141540) bei cisplatin-refraktären Ovarialkarzinom. (Kühnle, H. et al.; Georg-August-Univ., Zentrum Frauenheilkunde, Humboldtallee 3, 3400 Göttingen) S. 152.

Fine Needle Biopsy in Thoracic Tumours II. Fine Needle Biopsy of Chest Wall Tumours. (Sinner, W. N.; Dept. of Diagn. Radiology, Karolinska Hospital, S-10401 Stockholm) S. 156.

CA 19-9 in der Diagnostik und Differentialdiagnostik des exzitatorischen Pankreaskarzinoms. 2. Mitteilung. (Klapdor, R. et al.; Med. Kern- und Poliklinik, Univ. Krankenhaus Eppendorf, Martinstr. 52, 2000 Hamburg 20) S. 161.

Evaluation of Serum Ferritin in Leukaemia by two Different Ferritin Assays. (Kim, H. S. et al.; SD: Kaltwasser, J. P.; Zentrum der Inneren Medizin Abt. Hämatologie, Johann-Wolfgang-Goethe-Univ., Theodor-Stern-Kai 7, 6000 Frankfurt a. M. 70) S. 166.

European Journal of Clinical Microbiology

3 (1984), Nr. 3 (June)

Pneumocystis carinii: A Misunderstood Opportunist. (Pifer, L. L.; Dept. of Pediatrics, Section of Infectious Diseases, Pediatric Research Laboratory, Univ. of Tennessee Center for the Health Sciences, 956 Court Avenue, Room 3B09, Memphis, USA-Tennessee 38163) S. 169.

Another Look at Trimethoprim-Sulfamethoxazole: Its Role in Parenteral Therapy. (Sattler, F. R., Remington, J. S.; Dept. of Medicine, Milton S. Hershey Medical Center, Hershey, USA-Pennsylvania 17033) S. 174.

The Great Cephalosporin Wars. (Cohen, M. S.; Division of Infectious Diseases, UNC School of Medicine, 547 Burnett-Womack CSB 229H, Chapel Hill, USA-North Carolina 27514) S. 177.

Incidence, Predisposing Factors and Manifestations of Invasive Haemophilus influenzae Infections in Adults (Trollfors, B. et al.; Dept. of Infectious Diseases, Univ., S-901 85 Umeå) S. 180.

Pyridinium 2-Azo-p-Dimethylaniline Chromophore, a Chromogenic Reagent for Beta-Lactamase Testing Compared to Nitrocefin (Barlam, T., Neu, H. C.; Division of Infectious Diseases, Dept. of Medicine, College of Physicians & Surgeons, Columbia Univ., 630 West 168 Street, USA-New York 10032) S. 185.

Determination of the O-Serovars of *Pseudomonas aeruginosa* by Slide Coagglutination (Ansorg, R., Knoche, M.; Dept. of Medical Microbiology, Univ., Kreuzbergring 57, 3400 Göttingen) S. 190.

Interferon as an Adjuvant for Hepatitis B Vaccination in Non- and Low-Responder Populations (Grob, P. J. et al.; Section of Clinical Immunology, Dept. of Medicine, Univ. Hospital, Rämistr. 100, CH-8091 Zürich) S. 195.


Wound Infection Rates Following Preoperative Versus Intraoperative Commencement of Antibiotic Prophylaxis (Moesgaard, F. et al.; Inst. for Experimental Research in Surgery, Univ., 71 Norre Alle, DK-2100 Copenhagen) S. 199.

In Vitro Activity of Ticarcillin plus Clavulanic Acid Against Bacteria Isolated in Three Centers (Barry, A. L. et al.; The Clinical Microbiology Inst., P.O.Box 947, Tualatin, USA-Oregon 97062) S. 203.

Pathogenicity of Pilated and Encapsulated *Bacteroides fragilis* (Brook, I. et al.; Naval Medical Research Inst., National Naval Medical Center, Bethesda, USA-Maryland 20814) S. 207.

Enzyme-Linked Lectinosorbent Assay (ELLA) for Detecting *Bacillus anthracis* (Graham, K. et al.; Dept. of Microbiology and Immunology, Univ., Health Sciences Center, Louisville, USA-Kentucky 40292) S. 210.

Der vollautomatische Hämatologie-Analysator Sysmex CC-800



unser unerreichtes Spitzenmodell

Sysmex®

TOA MEDICAL ELECTRONICS CO., LTD.
Kobe, Japan

Alleinvertretung für die
Bundesrepublik Deutschland
und Berlin (West):

Colora Messtechnik GmbH
Postfach 12 40
7073 Lorch Württ.
Telefon: (0 71 72) 60 11
Telex: 7 248 886

Technische Büros
in Berlin, Düsseldorf,
Frankfurt, Hannover,
Lorch, München

colora

Analysentechnik
für Forschung, Medizin
und Umweltschutz

Fosfomycin in the Treatment of Cystic Fibrosis. (Katznelson, D. et al.; Dept. of Pediatrics "A" and the Infectious Diseases Unit, Chaim Sheba Medical Center, Tel-Hasomer, Israel 52621) S. 213.

A Case of Cryptic *Bacteroides fragilis* Septicemia (Watananakorn, C.; Infectious Disease Section, St. Elizabeth Hospital Medical Center, Youngstown, Ohio and Northeastern Ohio Univ. College of Medicine, Rootstown, USA-Ohio) S. 214.

Cross-Reactivity of Environmental Bacteria with Fluorescent-Antibody Conjugates for *Legionella pneumophila* (Glupczynski, Y. et al.; Dept. of Microbiology, Brugmann Hospital, Avenue J.-J. Croq. 1, B-1020 Brussels, Belgium) S. 215.

Campylobacter fetus subspecies jejuni in Senegal (Schneider, D. et al.; Nutrition Research Unit, Orstom, Dakar, BP. 1366, Dakar, Senegal) S. 216.

A Modified Method for Testing the Antimicrobial Susceptibility of Anaerobic Gram-Positive Cocci (Kaufmann, A. et al.; UCLA School of Dentistry Center for Periodontal Research, Los Angeles, USA-California 90024) S. 217.

In Vitro Activity of Ceftizoxime Combined with Aminoglycosides Against Clinical Bacterial Strains (Diez Enciso, M. et al.; Servicio de Microbiología, Ciudad Sanitaria La Paz, Paseo de la Castellana 261, E-34-Madrid) S. 219.

Fastidious Gram-Negative, Facultatively Anaerobic Rods: A Renewed Interest (Graevenitz, A.; Dept. of Medical Microbiology, Univ. CH-8028 Zurich) S. 223.

Phenotypic Differentiation of *Pasteurella* sensu stricto and the *Actinobacillus* Group (Mutters, R. et al.; Abt. Bakteriologie, Zentrum für Hygiene und Med. Mikrobiologie, Klinikum der Philipps-Univ., 3550 Marburg) S. 225.

Phenotypic Differentiation of *Cardiobacterium hominis*, *Kingella indologenes* and CDC group EF-4 (Bruun, B. et al.; Dept. of Clinical Microbiology, Bispebjerg Hospital, Amager Boulevard 80, DK-2300 Copenhagen) S. 230.

Rapid Identification of Capnocytophaga Isolated from Septicemic Patients (Kristiansen, J. E. et al.; Dept. of Clinical Microbiology, Gentofte County Hospital, DK-Lynby) S. 236.

The Cultivation and Rapid Enzyme Identification of DF-2 (Heltberg, O. et al.; Dept. of Diagnostic Bacteriology, Statens Seruminst., DK-2300 Copenhagen) S. 241.

Increased Frequency of Isolation of *Pasteurella* and *Actinobacillus* Species and Related Organisms (Sakazaki, R. et al.; Enterobacteriology Laboratories, National Inst. of Health, Kamiosaki, Shinagawa-ku, Tokyo 141, Japan) S. 244.

Relative Proportions of *Haemophilus* Species in the Throat of Healthy Children and Adults (Kuklinska, D., Kilian, M.; Dept. of Bacteriology, State Inst. of Hygiene, Chocimska 24, Warsaw, Poland) S. 249.

DF-2: A Fastidious Fermentative Gram-Negative Rod (Rubin, S. J.; Microbiology Division, Dept. of Pathology and Laboratory Medicine, St. Francis Hospital and Medical Center, Hartford, USA-Connecticut 06105) S. 253.

Pasteurella multocida Septicemia Not Associated with Primary Liver Disease (Grehn, M. et al.; Dept. of Medical Microbiology, Univ. Gloriustr. 32, CH-8028 Zürich) S. 258.

Adult Vertebral Osteomyelitis Caused by *Haemophilus influenzae* (Holzgang, J. et al.; Dept. of Internal Medicine Univ., CH-8028 Zurich) S. 261.

Endocarditis due to *Kingella kingae* (Ødum, L. et al.; Dept. of Diagnostic Bacteriology, Statens Seruminst., Amager Boulevard 80, DK-2300 Copenhagen) S. 263.

Septicemia Caused by *Kingella kingae* (Förstl, H. et al.; Max von Pettenkofer-Institut, Klinikum Großhadern, Med. Mikrobiologie, Marchioninistr. 15, 8000 München 70) S. 267.

Upper Urinary Tract Infection with *Gardnerella vaginalis* in a Woman (Loulergue, J. et al.; Laboratory of Microbiology, Trousseau, Hospital and Faculty of Medicine, F-37044 Tours Cedex) S. 270.

3 (1984), Nr. 4 (August)

Quantitative Urine Cultures Revisited (Stamm, W. E.; Dept. of Medicine, Division of Infectious Diseases, Harborview Medical Center, 325 Ninth Avenue, Seattle, Washington 98104, U.S.A.) S. 279.

Interferons and Viral Infections (Higgins, P. G.; MRC Common Cold Unit, Coombe Road, GB-Salisbury, Wiltshire, SP2 8BW) S. 282.

Host Defence Mechanisms, Antibiotics and Immunosuppressive Agents. A Complex Relationship (Miller, T. E.; Dept. of Medicine, Auckland Hospital, Park Road, Auckland, New Zealand) S. 285.

Influence of Subinhibitory Concentrations of Antibiotics on Opsonization and Phagocytosis of *Pseudomonas aeruginosa* by Human Polymorphonuclear Leukocytes (Milatovic, D.; Inst. of Medical Microbiology, Technical Univ., Ismaningerstr. 22, 8000 München 80) S. 288.

Rapid Enzymatic Characterization of Clinically Encountered Anaerobic Bacteria with the API ZYM System (Marler, L. et al.; N440 Univ. Hospital, Indiana Univ. Medical Center, 926 West Michigan Street, Indianapolis, Indiana 46223, U.S.A.) S. 294.

Evaluation of Commercial Test Systems for the Identification of Nonfermenters (Lampe, A. S., van der Reijden, T. J. K.; Dept. of Medical Microbiology, Univ. Hospital, NL-2333 AA Leiden) S. 301.

Changing Fecal *Escherichia coli* Flora During Travel (Ørskov, F. et al.; International Escherichia and Klebsiella Centre, Statens Seruminst., Amager Boulevard 80, DK-2300 Copenhagen) S. 306.

Spectral Analysis of Biochemical Reaction Used for Identification of Bacteria (Hilger, A. E., Lancaster, M. V.; Division of Medical Technology, Medical School Univ., Chapel Hill, North Carolina 27514, U.S.A.) S. 310.

A Nosocomial Epidemic of *Serratia liquefaciens* Urinary Tract Infection After Cystometry (Serruyts-Schoutens, E. et al.; Dept. of Microbiology, Hospital Univ. Eraseme, Route de Lennik 808, B-1070 Brussels) S. 316.

Modified Microdilution Susceptibility Test for *Staphylococci*, *Streptococci* and *Haemophilus* spp. (Fass, R. J., Helsel, V. L.; Division of Infectious Diseases, Dept. of Medicine, Univ., 410 West 10th Avenue, Columbus, Ohio 43210, U.S.A.) S. 318.

Brucellosis and Parenteral Drug Abuse (Romero-Vivas, J. et al.; Unidad de Enfermedades Infecciosas, Centro Especial „Ramon y Cajal“, E-Madrid 34) S. 319.

In Vitro Susceptibility of *Mycobacterium fortuitum* and *Mycobacterium chelonei* to Sulfa Diazine, Sulfoxazole and Sulfitazazole (Casan, M., Rodriguez, F.; Mycobacterium Reference Laboratory, Dept. of Microbiology, School of Medicine, Univ., E-Cordoba) S. 320.

A Latex Agglutination Technique for Rapid, Direct Identification of Pneumococci in Blood Cultures (Denis, F. et al.; Laboratoire de Bacteriologie-Virologie, C. H. U. Dupuytren, F-87031 Limoges) S. 321.

Susceptibility of *Campylobacter fetus* subsp. *jejuni* to Paromomycin (Freydere, A. M. et al.; Laboratoire de Microbiologie de l'hôpital de l'Antiquaille, F-69321 Lyon-Cedex 1) S. 322.

Heterogeneity of Apparently Pur Anaerobic Cultures: A Possible Source of Error in Susceptibility Testing (Reig, M., Baquero, F.; Servicio de Microbiología, Centro Especial Ramon y Cajal, Carretera de Colmenar Km 9, 100, E-Madrid 34) S. 323.

Current Topic: Ciprofloxacin. Microbiology and Pharmacology Introduction (Reeves, D. S.; Dept. of Medical Microbiology, Southmead Hospital, GB-Bristol) S. 327.

A Laboratory Assessment of Ciprofloxacin and Comparative Antimicrobial Agents (Shirley, L. et al.; Dept. of Microbiology, School of Pathology, South African Inst. for Medical Research and Univ. of the Witwatersrand, P.O. Box 1038, Johannesburg, Republic of South Africa) S. 328.

Comparative In Vitro Activity of Five Quinolone Derivatives and Five Other Antimicrobial Agents Used in Oral Therapy (Hoogkamp Korstanje, J. A. A.; Public Health Laboratory, Jelsumerstraat 6, NL-8917 EN Leeuwarden) S. 333.

The In Vitro and In Vivo Activity of Ciprofloxacin (Zeiler, H.-J., Grohe, K.; Bayer AG, Inst. for Chemotherapy, 5600 Wuppertal) S. 339.

The Activity of Ciprofloxacin and Other 4-Quinolones Against *Chlamydia trachomatis* and Mycoplasmas in Vitro (Ridgway, G. L. et al.; Dept. of Clinical Microbiology and Genito Urinary Medicine Univ., GB-London WC1) S. 344.

Mutational Resistance to 4-Quinolone Antibacterial Agents (Smith, J. T.; The Microbiology Section, Dept. of Pharmaceutics, Univ., 29-39 Brunswick Square, GB-London WC1N 1AX) S. 347.

Antibacterial Activity of Ciprofloxacin in Conventional Tests and in a Model of Bacterial Cystitis (Greenwood, D. et al.; Dept. of Microbiology and PHLS Laboratory, Univ., Queen's Medical Centre, GB-Nottingham NG7 2UH) S. 351.

Pharmacokinetics of Ciprofloxacin After Oral and Intravenous Administration in Healthy Volunteers (Wingender, W. et al.; Bayer AG, Pharma Research Center, 5600 Wuppertal) S. 355.

Diffusion of Ciprofloxacin into Prostatic Fluid (Dalhoff, A., Weidner, W.; Inst. for Chemotherapy, Pharma Research Center, Bayer AG, Postfach 101709, 5600 Wuppertal) S. 360.

Dose- and Sex-Independent Disposition of Ciprofloxacin (Höfler, D. et al.; Stadt. Kliniken, Med. Klinik III, Grafenstr. 9, 6100 Darmstadt) S. 363.

Comparison of the In Vitro Activity of Ciprofloxacin (Bay o 9887) and Norfloxacin Against Gastrointestinal Tract Pathogens (Diez-Enciso, M. et al.; Servicio de Microbiología, C. S. „La Paz“, Paseo de la Castellana, E-Madrid 34) S. 367.

In Vitro Activity of ciprofloxacin, Aztreonam and Ceftazidime Against *Serratia marcescens* and *Pseudomonas aeruginosa* (Righter, J.; Division of Microbiology, Toronto East General and Orthopaedic Hospital, 825 Coxwell Avenue, CN-Toronto, Ontario M4C 3E7) S. 368.

In Vitro Activity of Ciprofloxacin Against *Bacteroides*, *Haemophilus influenzae* and *Branhamella catarrhalis* (Olsson-Liljequist, B.; Dept. of Bacteriology, National Bacteriological Laboratory, S-10521 Stockholm) S. 370.

In Vitro Activity of Ciprofloxacin Against *Brucella melitensis* (Gobernado, M. et al.; Service of Microbiology and Unit of Experimental Bacteriology, La Fe Hospital, E-Vallencia 10) S. 371.

In Vitro Activity of Ciprofloxacin Against Clinical Isolates of *Chlamydia trachomatis* (Meier-Ewert, H. et al.; Dept. of Virology, Inst. of Medical Microbiology, Technical Univ., Biedersteinerstr. 29, 8000 München 40) S. 372.

Susceptibility of *Legionella* spp. to Quinolone Derivatives and Related Organic Acids (Ruckdeschel, G. et al.; Max-von-Pettenkofer-Inst., Klinikum Großhadern, Med. Mikrobiologie, Marchioninistr. 15, 8000 München 70) S. 373.

In Vitro Activity of Ciprofloxacin and Norfloxacin Against *Gardnerella vaginalis* (Machka, K.; Inst. of Medical Microbiology, Technical Univ., Ismaningerstr. 22, 8000 München 80) S. 374.

In Vitro Activity of Ciprofloxacin Against Group JK Corynebacteria (Machka, K., Balg, H.; Inst. of Medical Microbiology, Technical Univ., Ismaningerstr. 22, 8000 München 80) S. 375.

Bundesgesundheitsblatt

27 (1984), Nr. 10 (Oktober)

Versuch einer Bewertung von Nutzen und Risiko der Keuchhustenimpfung in der Bundesrepublik Deutschland (Wiedermann, G. et al.; Inst. f. Spezifische Prophylaxe u. Tropenmed. d. Univ., Kinderspitalgasse 15, A-1095 Wien) S. 297.

Fäkal Verunreinigung von Trinkwasser und Häufigkeit von Enteritis-Salmonellosen – ein ätiologischer Zusammenhang (Schindler, P.; Landesuntersuchungsamt f. das Gesundheitswesen Südbayern, Veterinärstr. 2, 8042 Oberschleißheim) S. 302.

Schutzimpfungen. Notwendigkeit – Wirkung / Nebenwirkungen – Impfpolitik (Spies, H.; Kinderpoliklinik, Pettenkoferstr. 8a, 8000 München 2) S. 305.

Meningokokkenzentrал – Jahresbericht 1983 (Berger, U.; Meningokokkenzentrale, Hygiene-Inst. d. Univ., Im Neuenheimer Feld 324, 6900 Heidelberg 1) S. 312.

Influenza 1983/1984 (Lange, W.; Nationales Referenzzentrum f. Influenza, Robert Koch-Inst. des BGA, Nordufner 20, 1000 Berlin 65) S. 314.

Merkblatt für Ausscheider von Salmonellen (Typhus, Paratyphus und Enteritiserreger) sowie von Ruhrbakterien (Merkblatt Nr. 12, Ausgabe 1984 (Hrsg. Bundesgesundheitsamt) S. 321.

27 (1984), Nr. 11 (November)

Prüfung und Bewertung von chemischen Stoffen im Hinblick auf den Gesundheitsschutz im Rahmen des Chemikaliengesetzes (Roll, R.; Bundesgesundheitsamt, Max von Pettenkofer-Inst., Abt. Chemikalienbewertung, Unter den Eichen 82-84, 1000 Berlin 45) S. 329.

10 Jahre 35 Lebensmittel- und Bedarfsgegenständegebot (Vierkötter, S.; Bundesgesundheitsamt, Max von Pettenkofer-Inst., Postfach 330013, 1000 Berlin 33) S. 334.

Methodik zur Ermittlung der Exposition von Anwendern bei bestimmungsgemäßem Umgang mit Pflanzenschutzmitteln (Batei, W. et al.; Leiter des Inst. für Landtechnische Grundlagenforschung d. FAL, 3300 Braunschweig-Völkenrode) S. 338.